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PROJECT DESCRIPTION: 
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Precedings HMP summary page. 
 
 
Project IDs 46315, 50637, 46881 
   
 
The overall goal of our Demonstration Project is to address the hypothesis that the gut 
microbiota plays a critical role in the pathogenesis of inflammatory bowel disease (IBD). To 
circumvent the confounding effects of mucosal inflammation and medications that independently 
bias microbial selection, we have set out to study a unique clinical model of ulcerative colitis 
(pouchitis) where the development and status of the gut microbiota can be assessed prospectively 
and relative to the outcome of disease. Pouchitis is an inflammatory condition of a surgically-
created pseudorectum that is unique to ulcerative colitis and rarely occurs when this procedure is 
performed for treatment of other non-IBD diseases.  Since the incidence of developing pouchitis 
within one year is over 50%, the likelihood of detecting antecedent changes in microbiota is 
high. Our multi-center study involves an integrated team of researchers with expertise in clinical 
manifestations of pouchitis (Univ. Chicago), cultivation of diverse microorganisms (MSU), 
molecular microbial ecology (MSU/UMich/MBL), and metagenomics (ANL). Our goal is to 
enroll up to 50 patients with pouchitis who will be followed clinically and endoscopically 
(sampling from the unprepped pouch) for a period of 18 months each. Though the use of high-
throughput, cost-effective technologies, which members of this team have played a key role in 
developing, we intend to demonstrate a critical role for the gut microbiome in the development 
of the dysregulated mucosal immune response that is the hallmark of IBD. In order to identify 
associations between the structure and dynamics of the gut microbial community and specific 
clinical endpoints, we will scan for markers in the fecal microbial community that are associated 
with specific, quantifiable measures of disease activity or progression. Collectively, these studies 
will provide insights into how enteric microbiota cause or contribute to the etiopathogenesis of 
human ulcerative colitis. This knowledge will lead the way to novel ways to monitor patients 
with IBD and to guide the development of novel preventative and therapeutic interventions. 
In accordance with the guidelines of the Human Microbiome Project (HMP), data generated 
by this study (NCBI Project ID 463154) will be subject to a 12 month publication moratorium 
from the date of data submission to dbGaP and SRA.   
 
 
 
 
II. DATA QUALITY:   
The Marine Biological Laboratory used 454 Life sciences recursive phase algorithm “beta 
pipeline” to recover an average of 890,000 reads that extend from our proximal primers through 
“landmark” evolutionary conserved sequences GGATTAGATACCC (E. coli 785-797) for V3 - 
V5 amplicons (455 ± 50nt) or TGGGCGTAAAG (E. coli 565-575) for V6 – V4 amplicons 
(490nt ± 50nt). Our analyses quarantine and exclude reads that do not exactly match the MIDs 
(Multiplex Identifiers) or proximal rRNA primers, reads containing one or more ambiguous base 
calls (Ns), reads that exhibit greater than 2 mismatches to the evolutionary conserved sequences, 
and reads lacking the “landmark” evolutionary conserved sequences within 50 nt of their 
predicted position. Based upon benchmarking activities, these quality control procedures result 
in an average error rate of fewer than one error/ 500 positions. Remaining high quality reads are 
assigned taxonomy using GAST which quarantines sequences without valid BLAST hits within 
an alignment of over 80% of the read length. The sequence data from MBL will be submitted to 
dbGaP and to SRA and posted on VAMPS (http://vamps.mbl.edu).  
For the shotgun metagenomic data analysis, Argonne National Laboratory’s quality control is 
implemented through procedures used to include/exclude a particular sequenced read for 
subsequent analysis: 
- Reads may not exhibit ambiguous base calls; those that do are removed from consideration. 
- Reads that exhibit an uncharacteristic length – with respect to the particular sequencing 
platform used and/or to the distribution of lengths among all sequenced reads. 
- Reads are screened to remove those that can be attributed to eukaryotic contamination; they 
are also screened to remove artificial duplicates. 
 
III. DATA ANALYSIS AND PUBLICATION PLANS:   
 
Data Analysis:   
For the shotgun metagenomic data analysis (Argonne), data are being processed through the 
Metagenomics RAST Server (MG-RAST) to determine the functional and metabolic content of 
each biological sample.  These functional and metabolic data are then examined with a variety of 
statistical tools (MG-RAST-stats) to identify correlations among the samples.  Similarities and/or 
differences are then resolved to the responsible functional and/or metabolic pathway(s).  The 
fidelity of such analyses is determined through the implementation of permutation (Monte-Carlo) 
based statistics.  The goal of all analyses is to identify biologically meaningful differences 
among samples based on observed variation in their identified sequence content. 
 
For analysis of functional genes, we are developing a functional gene dataset for each gene based 
on sequences extracted from HMP genomes and metagenomes, along with those from other 
major sequence repositories, and will automate regular updates of these datasets. We are using 
datasets to develop enhanced machine-learning classification tools similar to our naïve Bayesian 
16S rRNA classifier (RDP Classifier) to provide more detailed taxonomic resolution of the 
functional gene data. Methods are being developed to determine shotgun metagenome coverage 
of the functional genes using gene-abundance curves fitted to the targeted functional gene 
metagenome data.  
 
In order to identify associations between the structure and dynamics of the gut microbial 
community and specific clinical endpoints, we are employing approaches that have been broadly 
applied in genetic and gene expression studies for finding signatures of specific biological 
outcomes. In a manner analogous to gene expression or genome-wide association studies 
(GWAS) we are scanning for markers in the fecal microbial community that are associated with 
specific, quantifiable measures of disease activity or progression. For the purposes of our 
analysis, data generated by each of our analytic pathways will serve as analogous “markers” that 
will be associated with clinical variables/endpoints. Associations between individual markers 
(e.g. 16S V-region OTUs, metagenomic subsystems (MG-RAST), functional gene variants or 
specific cultivars) and quantitative clinical variables will be sought using data analysis models 
employed in statistical genetic analyses. The markers will initially be employed in a univariate 
analysis, but as analysis progresses, multivariate analysis will be performed.  
 
Publication Plans:  We hope to submit for publication the initial results of the metagenomic, 16S 
rRNA tag sequencing, cultivar, and functional gene analysis that describe the development of the 
pouch microbiome within the next 12 month before the termination of the embargo period.  
 
 
IV. DATA RELEASE PLAN:   
 
The data sharing plan will be coordinated by the Argonne National Laboratory, which will serve 
as the data coordination center for this consortium. The Argonne National Laboratory will be 
responsible for the sharing of data among consortium members and for upload of data to public 
databases such as dbGaP and SRA. We are working closely with the NIH and with the HMP 
Data Analysis and Coordination Center (DACC) to ensure that all required data is uploaded 
todbGaP and SRA. In our data management model, individual consortium members will be 
responsible for the data generated at each consortium site. The Argonne National Laboratory, in 
its role as data coordination center will be able to query each of the consortium databases for the 
purposes of analysis and also for transfer of data to the public HMP databases. We have 
budgeted for a limited amount of disk storage space required for initial analysis and data 
exchange, but have not budgeted the resources that would be required for long-term archival 
storage. We would anticipate that the HMP DACC will provide infrastructure and data standards 
for archival storage of data generated during this UH2/UH3 project.  
 
The first release of clinical and sequence data from the UH2 phase to dbGaP and SRA occurred 
on May 25, 2010. 
 
For each type of data, we anticipate the following data sharing/archive model: 
 
• Clinical data: using the Velos system in place at the University of Chicago and University of 
Michigan, clinical data are being transferred to controlled access site dbGaP. The Velos system 
will provide security for information that remains at U of C and U of M. The upload and 
archiving of protected health information to databases other than those maintained by the U of C 
and U of M will only be done as required by the NIH/HMP. We anticipate that we will uploaded 
de-identified metadata to dbGaP to provide maximal utility for the uploaded sequence data. 
 
• Sequence read and Picotitre TIFF files (the equivalent of sequence trace files for Sanger 
sequence) will be maintained at the sites that generated the data. Again, the Argonne National 
Laboratory will have the ability to access each of these individual databases and make the data 
available for consortium-wide analysis. These data will also be uploaded for archival storage at 
the HMP DACC if required and at Trace Archive. If, due to disk space requirements, any of this 
data were to be destroyed, this would not be done without consultation with the NIH project 
managers to ensure that archiving via the HMP DACC is completed. Metadata associated with 
any of sequence data (primarily the clinical data from the U of C that is maintained on Velos) 
will be linked via the Argonne National Laboratory data coordination efforts. These metadata 
and the links to the sequence data will also be transferred to dbGaP. 
 
• Cultivars from high throughput culture as performed at MSU will be stored at the MSU by the 
investigators located there. These cultivars will be made available to the awardees of the U54 
genome sequencing centers awarded under RFA-RM-08-001, and any other HMP-funded 
researchers. Once results are published in a peer-reviewed journal, any isolates that described 
will be made available to the general research community. In addition, these isolates will be 
deposited in BEI/ATCC, which has been contracted to be the repository for HMP reference 
isolates. 
 
• The results of analysis will be prepared for publication in peer-reviewed journals by the 
consortium. Much of the data analysis will be available in web-based format. The results of 16S 
tag sequencing analysis will be on the VAMPS site maintained by the MBL. The metagenomics 
analysis will be on the MG-RAST server maintained by ANL. Functional gene data analysis will 
be available on the site maintained by MSU.  
In accordance with the stated goals of the Human Microbiome Project, the data generated will be 
released to the public in a timely manner. Similarly, intellectual property issues will be dealt with 
by each institution in a manner that maximized public benefit of the data produced and the tools 
that are developed to deal with type of data. The consortium members have an outstanding track 
record of making data and analysis tools available to the public as exemplified the Ribosomal 
Database Project, SEED and the metagenomics RAST server and the VAMPS website. 
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